# Clinical Outcomes and Prognostic Biomarkers Exploration Between HER2 Low and HER2 Zero eBC Patients

> **NCT07561346** · — · COMPLETED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 2751 (actual)

## Conditions studied

- HER2 Low and HER2 Zero Patients With Operable Breast Cancer Treated With Dds-CT

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07561346
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07-15
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-09-15
- **Target enrollment:** 2751 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07561346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07561346, "Clinical Outcomes and Prognostic Biomarkers Exploration Between HER2 Low and HER2 Zero eBC Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07561346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*